We are live on
!
Find out more
ICM
ISZO Capital Management Portfolio holdings
AUM
$2M
1-Year Est. Return
35.61%
This Fund
S&P 500
This Quarter
Est. Return
+0.5%
1 Year Est. Return
+35.61%
3 Year Est. Return
+68.24%
5 Year Est. Return
+471.73%
10 Year Est. Return
–
AUM
$18.2M
AUM Growth
-$625K
(-3.3%)
Cap. Flow
-$90.8K
Cap. Flow
% of AUM
-0.5%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
1
Reduced
–
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lantheus
LNTH
|
+$9.04M |
| 2 |
CBL
CBL Properties
CBL
|
+$1.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$2.02M |
| 2 |
United Therapeutics
UTHR
|
+$2.02M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$1.54M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$1.11M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.65% |
| 2 | Real Estate | 7.32% |
| 3 | Energy | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Lantheus
LNTH
$6.49B
| $16.8M | 92.65% |
200,777
+100,777
| +101% | +$9.04M |
|
|
CBL
2
CBL Properties
CBL
$1.82B
| $1.33M | 7.32% |
+60,395
| New | +$1.42M |
|
3
Amplify Energy
AMPY
$161M
| $6.45K | 0.04% |
953
| – | – |
|
|
NVO
4
Novo Nordisk
NVO
$208B
| – | – |
-14,000
| Closed | -$1.11M |
|
|
5
Novartis
NVS
$297B
| – | – |
-22,000
| Closed | -$2.02M |
|
|
6
Invesco QQQ Trust
QQQ
$453B
| – | – |
-4,800
| Closed | -$1.54M |
|
|
7
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| – | – |
-2,500
| Closed | -$1.02M |
|
|
8
United Therapeutics
UTHR
$25.8B
| – | – |
-9,000
| Closed | -$2.02M |
|
|
FRC
9
DELISTED
First Republic Bank
FRC
| – | – |
-52,000
| Closed | -$727K |
|
|
CO
10
DELISTED
Global Cord Blood Corporation
CO
| – | – |
-279,495
| Closed | – |
|
Similar funds
LBC
TA
SCM
LCMP
GIP
STC
GC
DU
ISZO Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, ISZO Capital Management held 11 positions worth $18.2M, down 3.3% from $18.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
ISZO Capital Management's Q2 2023 filing shows 1 new, 1 increased and 8 closed positions. Its largest new stake was CBL Properties: 60,395 shares worth $1.33M. The largest sale was Novartis, an estimated $2.02M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 71% a quarter earlier, followed by Real Estate and Energy.
- ISZO Capital Management's largest Q2 2023 buy was CBL Properties: 60,395 shares worth $1.33M.
- ISZO Capital Management added most to Lantheus in Q2 2023, an estimated $9.04M increase.
- ISZO Capital Management fully exited Novartis in Q2 2023, selling an estimated $2.02M.
- ISZO Capital Management's ten largest holdings make up 100% of its $18.2M portfolio in Q2 2023.
- ISZO Capital Management opened 1 new position and closed 8 in Q2 2023.
- ISZO Capital Management's portfolio value fell 3.3% quarter-over-quarter to $18.2M.
Based on ISZO Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.